Drug Science Policy and Law - The Consciousness Library

Improved colour blindness symptoms associated with recreational psychedelic use: Results from the Global Drug Survey 2017

Drug Science Policy and Law 2020 Jec Anthony, Adam Winstock, Ja Ferris et al. 9 citations

It is well documented that psychedelic drugs can have a profound effect on colour perception. After previous research involving psychedelic drug ingestion, several participants had written to the authors describing how symptoms of their colour blindness had improved. The Global Drugs Survey runs the world’s largest annual online drug survey. In the Global Drugs Survey 2017, participants...

DOI: 10.1177/2050324520942345 Psilocybin Lysergic acid diethylamide Blindness Hallucinogen +2

2018: A watershed year for psychedelic science

Drug Science Policy and Law 2019 Jacob S. Aday, Christopher C. Davoli, Emily K. Bloesch 30 citations

While interest in the study of psychedelic drugs has increased over much of the last decade, in this article, we argue that 2018 marked the true turning point for the field. Substantive advances in the scientific, public, and regulatory communities in 2018 significantly elevated the status and long-term outlook of psychedelic science, particularly in the United States. Advances in the...

DOI: 10.1177/2050324519872284 Psilocybin Acknowledgement Hallucinogen Social science +1

Using the pharmacy retail model to examine perceptions and biases of a UK population sample towards regulation of specific psychoactive drugs

Drug Science Policy and Law 2019 Edward James, Thomas L Robertshaw, Michael Pascoe et al. 3 citations

Background: Contemporary research indicates that the legal classifications of cannabis (Schedule 2, Class B), 3,4-methylenedioxymethamphetamine (MDMA) (Schedule 1, Class A) and psilocybin (Schedule 1, Class A) in the United Kingdom are not entirely based on considerations of harm and therapeutic utility. The legal classifications of the substances discussed are typically determined by...

DOI: 10.1177/2050324519876123 Psilocybin Cannabis MDMA Pharmacy +3

The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985)

Drug Science Policy and Law 2018 Torsten Passie 115 citations

3,4-Methylenedioxymethamphetamine (MDMA), also known as ecstasy, was first synthesized in 1912 but first reached widespread popularity as a legal alternative after the much sought-after recreational drug 3,4-methylenedioxy-amphetamine (MDA) was made illegal in 1970. Because of its benign, feeling-enhancing, and nonhallucinatory properties, MDMA was used by a few dozen psychotherapists in the...

DOI: 10.1177/2050324518767442 MDMA Ecstasy Feeling Amphetamine +3

Pharmacies as potential providers of harm reduction services: A preliminary online survey

Drug Science Policy and Law 2018 Edward James, Thomas L Robertshaw, Andrew D. Westwell et al. 4 citations

Background Recreational drug use is a major cause of disease, injury, physical and mental impairment and death in developed countries such as the United Kingdom and the United States. Alcohol, tobacco, cannabis, 3,4-methylenedioxymethamphetamine (MDMA) and psilocybe mushrooms are recreational drugs with capacity to cause harm. Cannabis, MDMA and psilocybin have reported therapeutic...

DOI: 10.1177/2050324518767441 Cannabis Psilocybin MDMA Harm reduction +6

Constructing drug effects: A history of set and setting

Drug Science Policy and Law 2017 Ido Hartogsohn 459 citations

Set and setting is a term which refers to the psychological, social, and cultural parameters which shape the response to psychedelic drugs. The concept is considered fundamental to psychedelic research and has also been used to describe nonpharmacological factors which shape the effects of other agents such as alcohol, heroin, amphetamines, or cocaine. This paper reviews the history and...

DOI: 10.1177/2050324516683325

Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy

Drug Science Policy and Law 2017 James W. B. Elsey 59 citations

The potential of psychedelic drugs in the treatment of mental health problems is increasingly being recognized. However, relatively little thrust has been given to the suggestion that individuals without any mental health problems may benefit from using psychedelic drugs, and that they may have a right to do so. This review considers contemporary research into the use of psychedelic drugs in...

DOI: 10.1177/2050324517723232 Mental health Drug

Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine/ ecstasy users in the United States and the United Kingdom

Drug Science Policy and Law 2017 Alan K. Davis, Harold Rosenberg 22 citations

Both recreational and problematic MDMA/ecstasy users could benefit from employing harm reduction interventions intended to preserve health and prevent negative consequences. To evaluate whether use of such interventions varied by country of residence and frequency of ecstasy use, we used web-based surveys to assess how often 104 lower-frequency and higher-frequency American ecstasy users and 80...

DOI: 10.1177/2050324517711069 Ecstasy MDMA Harm reduction Residence +4

Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary

Drug Science Policy and Law March 24, 2015 Ben Sessa, Friederike Meckel Fischer 39 citations

Underground psychedelic-assisted psychotherapy has persisted in Europe despite the banning of the substances LSD and MDMA in the 1960s and 1980s, respectively. This article describes the work of a Zurich-based psychotherapist providing individual and group psycholytic psychotherapy, whose practice persisted for several years before she was arrested in 2009. The article provides commentary on...

DOI: 10.1177/2050324515578080 MDMA Psychotherapist Mainstream Context archaeology +2

Papers